Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
World J Clin Cases ; 11(26): 6206-6212, 2023 Sep 16.
Article in English | MEDLINE | ID: mdl-37731580

ABSTRACT

BACKGROUND: Patients with trisomy 8 consistently present with myeloid neoplasms and/or auto-inflammatory syndrome. A possible link between myelodysplastic syndromes (MDS) with trisomy 8 (+8-MDS) and inflammatory disorders is well recognized, several cases having been reported. However, inflammatory disorders in patients without MDS have been largely overlooked. Generally, Behçet's disease is the most common type in +8-MDS. However, inflammatory disorders with pulmonary involvement are less frequent, and no effective treatment has been established. CASE SUMMARY: A 27-year-old man with recurrent fever, fatigue for > 2 mo, and unconsciousness for 1 day was admitted to our emergency department with a provisional diagnosis of severe pneumonia. Vancomycin and imipenem were administered and sputum collected for metagenomic next-generation sequencing. Epstein-Barr virus and Mycobacterium kansasii were detected. Additionally, chromosomal analysis showed duplications on chromosome 8. Two days later, repeat metagenomic next-generation sequencing was performed with blood culture. Cordyceps portugal, M. kansasii, and Candida portugal were detected, and duplications on chromosome 8 confirmed. Suspecting hematological disease, we aspirated a bone marrow sample from the iliac spine, examination of which showed evidence of infection. We added fluconazole as further antibiotic therapy. Seven days later, the patient's condition had not improved, prompting addition of methylprednisolone as an anti-inflammatory agent. Fortunately, this treatment was effective and the patient eventually recovered. CONCLUSION: Severe inflammatory disorders with pulmonary involvement can occur in patients with trisomy 8. Methylprednisolone may be an effective treatment.

2.
Ann Palliat Med ; 11(12): 3794-3803, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36636003

ABSTRACT

BACKGROUND: Acute respiratory distress syndrome (ARDS) is a very common disease in the intensive care unit (ICU), with rapid progression and high mortality. Infections caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can easily progress to ARDS in severely ill patients. Early and rapid diagnosis as well as screening for ARDS during treatment is very important. Owing to the particularity of patients with coronavirus disease 2019 (COVID-19), computed tomography (CT) examination is not always possible, and chest radiographs have a low sensitivity and specificity for the diagnosis of lung diseases. Therefore, bedside lung ultrasound (LUS) can be used as a new tool for the diagnosis of ARDS in patients with COVID-19. In the non-gravity-dependent pulmonary field, there are bilateral non-uniform B lines. In the dorsal pulmonary field, the B lines are denser and even appears as "white lung". Areas of consolidation are usually found in the dorsal pulmonary field, especially at the basilar part, with static or dynamic air bronchogram sign. In the fused B-line area, the "lung slip" usually decreases or disappears. The pleural line is irregular, thickened, and rough, with multiple small consolidations. The pulmonary ultrasound findings of primary and secondary ARDS were similar. CASE DESCRIPTION: In the abovementioned context, we share our experience with the treatment of one critical COVID-19 case and review the literature. An 81-year-old male patient with ARDS which is caused by COVID-19. The implementation of prone ventilation was guided by LUS, and we found that the pulmonary edema in the gravity-dependent area did improve over time. After 9 h of prone ventilation, the consolidation of the posterior area began to open. LUS shows the change from fragment sign to B line. After 16 h, the B-line was educed, indicating that pulmonary edema was improving. The oxygenation could be improved. Pulmonary ultrasound makes the monitoring of prone ventilation visualized. As the same time, the patient was accepted high-flow nasal oxygen, mechanical ventilation and treated with oseltamivir, lopinavir/ritonavir, abidol and cefoperazone-sulbactam. CONCLUSIONS: LUS-guided treatment was the key factor in the successful treatment of this case.


Subject(s)
COVID-19 , Pulmonary Edema , Respiratory Distress Syndrome , Male , Humans , Aged, 80 and over , COVID-19/complications , COVID-19/diagnostic imaging , COVID-19/therapy , SARS-CoV-2 , Critical Illness , Respiratory Distress Syndrome/diagnostic imaging , Respiratory Distress Syndrome/therapy , Lung/diagnostic imaging , Ultrasonography, Interventional
4.
Sci Rep ; 7: 44979, 2017 03 21.
Article in English | MEDLINE | ID: mdl-28322337

ABSTRACT

Sedatives are commonly used for mechanically ventilated patients in intensive care units (ICU). However, a variety of sedatives are available and their efficacy and safety have been compared in numerous trials with inconsistent results. To resolve uncertainties regarding usefulness of these sedatives, we performed a systematic review and network meta-analysis. Randomized controlled trials comparing sedatives in mechanically ventilated ICU patients were included. Graph-theoretical methods were employed for network meta-analysis. A total of 51 citations comprising 52 RCTs were included in our analysis. Dexmedetomidine showed shorter MV duration than lorazepam (mean difference (MD): 68.7; 95% CI: 18.2-119.3 hours), midazolam (MD: 10.2; 95% CI: 7.7-12.7 hours) and propofol (MD: 3.4; 95% CI: 0.9-5.9 hours). Compared with dexmedetomidine, midazolam was associated with significantly increased risk of delirium (OR: 2.47; 95% CI: 1.17-5.19). Our study shows that dexmedetomidine has potential benefits in reducing duration of MV and lowering the risk of delirium.


Subject(s)
Critical Care , Hypnotics and Sedatives/therapeutic use , Intensive Care Units , Respiration, Artificial , Critical Care/methods , Humans , Hypnotics and Sedatives/adverse effects , Odds Ratio , Outcome Assessment, Health Care , Publication Bias
5.
J Thorac Dis ; 6(7): 995-1003, 2014 Jul.
Article in English | MEDLINE | ID: mdl-25093098

ABSTRACT

BACKGROUND AND OBJECTIVES: Hyperlactatemia has long been associated with poor clinical outcome in varieties of intensive care unit (ICU) patients. However, the impact of temporal changes in lactate has not been well established and there are some shortcomings in model building in previous studies. The present study aims to investigate the association of initial lactate and normalization time with hazard by using fractional polynomial Cox proportional hazard model. METHODS: A large clinical database named Multiparameter Intelligent Monitoring in Intensive Care II (MIMIC-II) was employed for analysis. Demographics, comorbidities, laboratory findings were extracted and were compared between survivors and non-survivors by using univariable analysis. Cox proportional hazard model was built by purposeful selection of covariate with initial lactate (L0) and normalization time (T) remaining in the model. Best fit model was selected by using deviance difference test and comparisons between fractional polynomial regression models of different degrees were performed by using closed test procedure. MAIN RESULTS: A total of 6,291 ICU patients were identified to be eligible for the present study, including 1,675 non-survivors and 4,616 survivors (mortality rate: 26.6%). Patients with lactate normalization had significantly reduced hazard rate as compared to those without normalization (log-rank test: P<0.05). The best powers of L0 in the model were -2 and -1 with the deviance of 19,944.51, and the best powers of T were 0.5 and 3 with the deviance of 7,965.63. The adjusted hazard ratio for the terms L0(-2) and L0(-1) were 1.13 (95% CI: 1.09-1.18) and 0.43 (95% CI: 0.34-0.54); and the adjusted hazard ratio for the terms T(0.5) and T(3) were 7.42 (95% CI: 2.85-19.36) and 3.06×10(-6) (95% CI: 3.01×10(-11)-0.31). CONCLUSIONS: Initial lactate on ICU admission is associated with death hazard and the relationship follows a fractional polynomial pattern with the power of -2 and -1. Delayed normalization of lactate is predictive of high risk of death when it is measured within 150 hours after ICU admission.

6.
ASAIO J ; 59(6): 622-6, 2013.
Article in English | MEDLINE | ID: mdl-24172268

ABSTRACT

Dose determination in continuous renal replacement therapy (CRRT) is controversial. Most clinical trials use effluent flow rate as a surrogate of the dose. However, such definition may overestimate actually delivered dose due to declining filter function. The current study aimed to determine the difference between prescribed and delivered clearance and its association with transmembrane pressure. Hemofiltration was done in a mixed pre- and postdilution mode. Creatinine concentrations in serum and effluent fluid were measured simultaneously at 4, 10, 16, 28, 40, 52, and 64 hours for an individual hemofilter. Prescribed clearance (K) was estimated as the effluent flow rate corrected for predilution, and delivered clearance (Kx) was estimated using the ratio of serum and effluent creatinine. A total of 60 patients involving 248 filters were included in our analysis. The mean filter life span was 37.7 hours (standard deviation: 17.6). K overestimated Kx by 9.3% (95% confidence interval: -4.4% to 32.3%). The differences between K and Kx increased progressively over time. Transmembrane pressure was significantly correlated to the reduction with a Spearman's rho of 0.44 (p < 0.001). K significantly overestimates Kx during CRRT, and the difference increases progressively over time. Filters are recommended to be changed at 48-72 hours on a routine basis.


Subject(s)
Creatinine/analysis , Hemofiltration/methods , Aged , Creatinine/metabolism , Female , Humans , Male , Middle Aged , Renal Replacement Therapy/methods
7.
BMC Nephrol ; 14: 235, 2013 Oct 28.
Article in English | MEDLINE | ID: mdl-24164963

ABSTRACT

BACKGROUND: Chloride administration has been found to be harmful to the kidney in critically ill patients. However the association between plasma chloride concentration and renal function has never been investigated. METHODS: This was a retrospective study conducted in a tertiary 24-bed intensive care unit from September 2010 to November 2012. Data on serum chloride for each patient during their ICU stay were abstracted from electronic database. Cl0 referred to the initial chloride on ICU entry, Cl(max), Cl(min) and Cl(mean) referred to the maximum, minimum and mean chloride values before the onset of AKI, respectively. AKI was defined according to the conventional AKIN criteria. Univariate and multivariable analysis were performed to examine the association of chloride and AKI development. RESULTS: A total of 1221 patients were included into analysis during study period. Three hundred and fifty-seven patients (29.2%) developed AKI. Cl(max) was significantly higher in AKI than in non-AKI group (111.8 ± 8.1 vs 107.9 ± 5.4 mmol/l; p < 0.001); Cl0 was not significantly different between AKI and non-AKI patients; Cl(mean) was significantly higher in AKI than non-AKI (104.3 ± 5.8 vs 103.4 ± 4.5; = 0.0047) patients. Cl(max) remained to be associated with AKI in multivariable analysis (OR: 1.10, 95% CI: 1.08-1.13). CONCLUSION: Chloride overload as represented by Cl(mean) and Cl(max) is significantly associated with the development of AKI.


Subject(s)
Acute Kidney Injury/blood , Acute Kidney Injury/mortality , Chlorides/blood , Biomarkers/blood , China/epidemiology , Critical Illness , Female , Humans , Male , Middle Aged , Prevalence , Reproducibility of Results , Risk Factors , Sensitivity and Specificity , Survival Rate
8.
Trials ; 14: 32, 2013 Feb 01.
Article in English | MEDLINE | ID: mdl-23374652

ABSTRACT

BACKGROUND: Hemodynamic monitoring is very important in critically ill patients with shock or acute respiratory distress syndrome(ARDS). The PiCCO (Pulse index Contour Continuous Cardiac Output, Pulsion Medical Systems, Germany) system has been developed and used in critical care settings for several years. However, its impact on clinical outcomes remains unknown. METHODS/DESIGN: The study is a randomized controlled multi-center trial. A total of 708 patients with ARDS, septic shock or both will be included from January 2012 to January 2014. Subjects will be randomized to receive PiCCO monitoring or not. Our primary end point is 30-day mortality, and secondary outcome measures include ICU length of stay, days on mechanical ventilation, days of vasoactive agent support, ICU-free survival days during a 30-day period, mechanical-ventilation-free survival days during a 30-day period, and maximum SOFA score during the first 7 days. DISCUSSION: We investigate whether the use of PiCCO monitoring will improve patient outcomes in critically ill patients with ARDS or septic shock. This will provide additional data on hemodynamic monitoring and help clinicians to make decisions on the use of PiCCO. TRIAL REGISTRATION: http://www.clinicaltrials.gov NCT01526382.


Subject(s)
Cardiac Output , Critical Care/methods , Monitoring, Physiologic/instrumentation , Research Design , Respiratory Distress Syndrome/diagnosis , Shock, Septic/diagnosis , China , Clinical Protocols , Critical Illness , Equipment Design , Humans , Length of Stay , Organ Dysfunction Scores , Predictive Value of Tests , Prospective Studies , Respiration, Artificial , Respiratory Distress Syndrome/mortality , Respiratory Distress Syndrome/physiopathology , Respiratory Distress Syndrome/therapy , Shock, Septic/mortality , Shock, Septic/physiopathology , Shock, Septic/therapy , Time Factors , Treatment Outcome , Vasoconstrictor Agents/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...